Présentation de l'entreprise
Check-Cap Ltd., whose ticker is MBAI, operates as a clinical stage medical diagnostics company that specializes in capsule-based screening technology products designed to advance non-invasive diagnostic capabilities. The firm functions within the broader Healthcare sector, specifically targeting the Diagnostics & Research industry, which implies a focus on developing and commercializing technologies used for medical testing and disease identification. As of the latest available data, the company possesses a market capitalization of $11.95M, while the annual revenue and employee count are not disclosed in the provided financial records, indicating a micro-cap status. This limited market capitalization suggests that the company is in an early-stage development phase where capital markets have not yet assigned a large valuation to its potential, reflecting the inherent risks and high uncertainty associated with clinical-stage biotechnology firms that have not yet achieved consistent commercial profitability.
Santé financière
The company reports a net income of $-13,624,000 over the trailing twelve months, while the EBITDA stands at $-3,756,500, revealing a significant gap between operational earnings and bottom-line profits that highlights a cost structure heavily burdened by non-operating expenses or significant one-time charges. Additionally, the revenue figure for the trailing twelve months is not available, which prevents a direct calculation of operating leverage but emphasizes the difficulty in assessing traditional profitability metrics for a firm with no reported revenue. The free cash flow is reported at $-1,058,125, indicating a negative cash generation capability that limits the company's financial flexibility and necessitates reliance on external financing to fund ongoing research and development activities. Regarding margins, the gross margin is 0.0%, the operating margin is 0.0%, and the profit margin is 0.0%, figures that collectively indicate the company has not yet achieved commercial revenue sufficient to cover its costs of goods sold or operating expenses to generate a positive margin. In terms of balance sheet strength, the company holds $1.42M in cash against $139,000 in debt, resulting in a debt-to-equity ratio of 3.69, which suggests a highly leveraged position relative to its equity base despite the low absolute debt amount. The current ratio is 0.71, a metric that indicates the company's current assets are insufficient to cover its current liabilities without relying on external funding or asset liquidation in the short term. Furthermore, the Return on Equity is -130.1% and the Return on Assets is -20.8%, metrics that reveal management's ineffectiveness in generating positive returns on the capital invested by shareholders or held on the balance sheet over the reporting period.
Évaluation de la valorisation
The trailing P/E ratio is not available due to the lack of positive net income, and the forward P/E is also not available, which implies that the market cannot value the stock based on earnings multiples and must instead rely on alternative valuation methods given the company's unprofitable status. The price-to-book ratio is 2.55, a figure that indicates the market is currently valuing the company at a premium of 155% over its book value, suggesting investor optimism regarding the future commercialization of its capsule technology despite current financial losses. Since the price-to-sales ratio is not available and the EV/EBITDA stands at -2.21, these alternative valuation metrics suggest that the stock is being priced based on asset value and potential future cash flows rather than current earnings power or sales multiples. The 52-week high is $3.92 and the 52-week low is $0.59, and without a specific current price to calculate the exact percentage deviation, the stock's position relative to this range remains undefined in the provided data, though the wide spread indicates high volatility. The beta is 0.79, a value that explains the stock's price volatility is lower than the broader market, meaning the stock tends to move less dramatically than the overall market index during periods of general economic fluctuation.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both not available, which prevents a direct comparison of earnings growth rates against revenue growth to determine if the company is expanding its profit margins or losing them as sales increase. Since the company does not pay dividends, the dividend yield is not available and the payout ratio is 0.0%, indicating that the firm reinvests all available earnings, or in this case, its remaining capital, back into its operations and research rather than distributing income to shareholders. The absence of a dividend policy combined with negative free cash flow suggests the company is in a growth phase where capital preservation is prioritized over income distribution, forcing it to seek external equity or debt financing to sustain operations. Overall, the growth and income profile for Check-Cap Ltd. is characterized by a lack of historical financial data, negative returns on capital, and a total reliance on capital markets to fund its clinical stage development without providing any current income to investors.